Third Melaseq validation study published in PLOS ONE

New research published in PLOS ONE, shows that (i) the Melaseq™ test can also be used on skin biopsy tissue, (ii) the test can also identify high/low-risk melanoma, therefore predict a patient’s length of survival and (iii) the 38 microRNAs analysed  Min each sample are known to regulate a significant number of immunotherapy targets. More info.